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pared to well-moderately differentiated tumor (p = 0.0172). Having poorly differenti-
ated tumor was related to higher death rate immediately after diagnosis, but this 
disadvantageous effect gradually vanished over time. Fourteen comorbidity con-
ditions were significantly associated with shorter time-to-death. ConClusions: 
Effective control of comorbidity in PCa patients should help improve life expectancy 
and lead to prolonged survival. Further research is needed to understand mecha-
nisms in which individual and contextual factors impact PCa survival.
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objeCtives: Bevacizumab is a humanized monoclonal antibody that produces 
angiogenesis inhibition by inhibiting vascular endothelial growth factor A (VEGF-A). 
Bevacizumab was approved for combination use with standard chemotherapy for 
metastatic colon cancer. This research aims to conduct a systematic review on 
meta-analysis and cost-effectiveness analysis on standard chemotherapy plus 
bevacizumab for patients with metastatic colorectal cancer (mCRC) to explore the 
efficacy, safety and cost-effectiveness on the addition of bevacizumab. Methods: 
A systematic literature search on both meta-analysis and cost-effectiveness analy-
sis of chemotherapy plus bevacizumab on databases was carried out in several 
databases, such as MEDLINE, PubMed, CNKI chemotherapy. Articles were included 
based on specific inclusion and exclusion criteria. Results: Six included analyses 
indicate that chemotherapy plus bevacizumab significantly prolonged progression-
free survival (PFS) and overall survival (OS). The risk of hypertension, bleeding and 
proteinuria are significantly increased, whereas there are no significant differences 
on gastric perforation, thrombosis. Eleven cost-effectiveness analysis demonstrate 
that the addition of bevacizumab lead to higher medical cost and health care cost. 
In most countries involved in this review, chemotherapy plus bevacizumab is not 
cost-effective comparing with standard chemotherapy. However, the medical and 
health care cost of using bevacizumab is lower than cetuximab. ConClusions: 
The addition of bevacizumab significantly increases survival benefits and slightly 
leads to more adverse events. Due to higher cost of bevacizumab, it is not cost-
effective therapy for mCRC patients. According to the potential considerable differ-
ences on economic status, epidemiology, clinical effectiveness, the generalizability 
of included meta-analyses and cost-effectiveness analyses need to be taken into 
account. Analyses based on China local data should be processed in the future.
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objeCtives: This study assessed whether sequential treatment of chemotherapy 
with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) ver-
sus chemotherapy alone as the first-line therapy improved treatment outcomes 
in patients with advanced non-small cell lung cancer (NSCLC) who do not receive 
EGFR gene testing in the resource-limited care setting. Methods: We searched 
seven databases up to November 30th, 2013. Randomized controlled trials (RCTs) 
were included. Pre-specified outcomes included progression-free survival (PFS), 
overall survival (OS), objective response rate (ORR), quality of life (QoL) and adverse 
events. Two investigators independently selected studies, assessed the risk of bias, 
and collected data. Results: Four trials involving 1,274 patients were eligible for 
inclusion. If treated unselectively, sequential therapy significantly increased PFS 
(hazard ratio[HR] 0.59, 95% CI 0.49-0.71), OS (HR 0.85, 95% CI 0.75-0.97), and ORR (risk 
ratio[RR] 2.03, 95% CI 1.46-2.84) in NSCLC patients. However, the benefits appeared to 
be achieved in patients with EGFR M+ NSCLC (PFS: HR 0.25, 95% CI 0.16-0.39; OS: HR 
0.48, 95% CI 0.27-0.85; and ORR: RR 5.74, 95% CI 2.86-11.50), but not in patients with 
EGFR-WT NSCLC (PFS: HR 0.97, 95% 0.69-1.36; OS: HR 0.77, 95% 0.53-1.11; and ORR: RR 
0.74, 95% 0.41-1.34). Sequential therapy caused more skin rash (5.19% vs. 0.63%; RR 
7.36, 95% CI 2.79-19.44). Nevertheless, there was no statistically significant difference 
between groups in other adverse events. ConClusions: Although sequential use 
of chemotherapy and EGFR-TKI as first line therapy seemed to improve effects in 
NSCLC patients who did not receive gene testing, the apparent benefits were primar-
ily attributable to the improvement in patients who had EGFR M+ cancer. Due to the 
limited power of study, the sequential therapy does not appear to improve treat-
ment outcomes in patients with EGFR-WTcancer. Randomized trials that specifically 
address the effect of sequential therapy in advanced NSCLC patients are warranted.
PCN5
a systematiC literature review oN risk faCtors for CerviCal CaNCer 
iN ChiNese PoPulatioN
Jiang Y1, Hu SY2, Hernandez Donoso L3, Li X4, Zheng MH5, Zhao FH2
1Amaris, London, UK, 2Cancer Institute and Hospital, Chinese Academy of Medical Sciences, 
Beijing, China, 3GlaxoSmithKline Vaccines, Shanghai, China, 4GlaxoSmithKline Vaccines, Wavre, 
Belgium, 5GlaxoSmithKline Vaccines, Beijing, China
objeCtives: In China, the annual number of cervical cancer (CC) cases is expected 
to increase between 42,000 and 187,000 in 2050. Previous meta-analysis reported 
gestational history and sexual behaviour as the main risk factors for CC in China. 
This study aims at updating these findings with a comprehensive systematic lit-
erature review. Methods: The systematic literature review retrieved citations 
from MEDLINE, MEDLINE-IN-PROCESS and EMBASE, and three Chinese databases, 
CNKI, Wanfang Data and CQVIP, using PICOS framework. The target population 
was Chinese adolescent or adult females. All observational studies irrespective 
of intervention or comparator reporting risk factors for CC were included. Search 
EET antagonist,14,15-EEZE (10-5 M) did not inhibit relaxation to WX-III-287-19, but 
inhibited relaxation to 5,6-8,9-11,12 and 14,15 EETs. Preincubation with the ibe-
riotoxin (10-5 M) only partially inhibited the relaxation induced by WX-III-287-19 
whereas high K+  (60 mM) significantly inhibited relaxation to WX-III-287-19. In 
whole cell-attached patches of isolated bovine coronary arterial smooth muscle 
cells, WX-III-287-19 did not alter activation of large-conductance, calcium-activated 
K+ channels.In U-46619-preconstricted rabbit aortic rings, WX-III-287-19 caused 
relaxation; however, relaxations were not observed in arteries preconstricted with 
either high K+ (60 mM) and pheynylephrine (10-5 M). These results indicate that 
WX-III-287-19 is a potent coronary vasorelaxant and may act as a thromboxane 
receptor antagonist.
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During the development of society and the economy, the rapid growth of health care 
costs has become a burden on the worldwide health protection system. The problem 
of aging populations and a changing disease spectrum as well as the progress and 
change in health care technology, therefore, the health care costs increased. The 
major problem of many countries is how to use drug utilization review (DUR) and 
pharmacoeconomic evaluation to improve and optimize the configuration of medi-
cal and health resources. This paper presents the importance of drug utilization 
review and pharmacoeconomic evaluation and discusses the application of them 
in new drug research and development, drug pricing, the selection of NRDL, and 
promoting rational drug use. The quality of drug utilization review and pharmaco-
economic evaluation is critical. Furthermore, this paper analyzes problems and chal-
lenges of drug utilization review and pharmacoeconomic evaluation. Government 
departments, medical institutions, pharmaceutical companies, and research insti-
tutes should use them to solve their problems. Key words:  Drug utilization review, 
Pharmaoeconomic evaluation, Pharmacoeconomics.
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objeCtives: To review prevalence and risk factors of febrile neutropenia in breast 
cancer patients received adjuvant paclitaxel treatment. Methods: retrospective 
chart review of 18 breast cancer patients received 146 cycles of adjuvant paclitaxel 
for prevention of breast cancer recurrence during 2011 at Phramongkutklao hospi-
tal, Bangkok, Thailand Results: Average age of patient in this study was 54.6+/-10.5 
years old. Paclitaxel were given to patients in 7 dosage regimens. The most common 
dosage regimen (62/146, 42.5%) was weekly paclitaxel 12 cycles post doxorubicin and 
cylcophosphamide (AC) regimen. There were 3 febrile neutropenia cases out of 18 
patients who recieved 154 cycles of adjuvant paclitaxel treatment. Prevalence of febrile 
neutropenia in this study was 2.05%. Prevalence of neutropenia in this study was 7.5% 
(11 cases out of 146 treatment cycles). Dosage regimen of paclitaxel (> 100 mg/m2 /cycle 
) associated with neutropenia was found to associated with neutropenia. Other com-
mon adverse events found in this study were peripheral neuropathy in 9 cases (50%), 
nausea/vomiting 7 cases (29%) and muscle weakness 6 cases (25%). ConClusions: 
Neutropenia from higher dose (> 100 mg/m2) of paclitaxel was common and trend to 
associated with febrile neutropenia in breast cancer patients treated with this drug. 
Closely monitoring and supportive therapy is needed in the patients recieving higher 
paclitaxel dose to prevent febrile nutropenia during adjuvant paclitaxel treatment.
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objeCtives: Few studies have looked at the independent contribution that individ-
ual-level and contextual factors make to prostate cancer (PCa) survival. The aim is to 
investigate individual and contextual factors contributing to overall PCa survival in 
Florida. Methods: A random sample of 6453 cases diagnosed with prostate cancer 
between 10/1/2001 and 12/31/2007 in the Florida Cancer Data System provided data 
on: individual demographics and clinical information. Census 2000 was linked to 
patient data. Comorbidity was computed following Elixhauser Index. Estimated 
survival probability curve was generated using the Kaplan-Meier estimator. Wei, 
Lin and Weissfeld (WLW) survival model was adopted for the multivariate analysis. 
The observation times were censored at June 30, 2012 for patients who were alive 
at end of study. Results: Range of observation period was 5 to 3925 days, where 
1100 patients (17.05%) died. Older diagnosis age was associated with shorter time-to-
death. Overall death rate for African American patients was 14.3% higher than that 
of Caucasian patients, although this relationship was not significant (p = 0.2305). 
Uninsured patients had a 66.7% higher mortality rate than that of patients holding 
private insurance (p = 0.0351). Current smokers had a 62.4% higher mortality rate 
than that of non-current smokers (p < 0.0001). Higher hazard of overall mortality 
was associated with being diagnosed with advanced stage compared to localized 
stage (HR = 1.89, p < 0.0001) and having undifferentiated or unknown tumor com-
